These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23697980)

  • 21. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
    Gomez-Pinillos A; Ferrari AC
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.
    Adamson PC
    Leukemia; 1994; 8 Suppl 3():S22-5. PubMed ID: 7808020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aiming at neuroblastoma and hitting other worthy targets.
    Schor NF
    J Child Neurol; 2013 Jun; 28(6):768-73. PubMed ID: 23576410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [mTOR complexes -- molecular spiders in molecular networks].
    Kopper L; Tímár J
    Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the novel all-trans retinoic acid-related resistance gene HA117 in pediatric solid tumors.
    Duan W; Jin X; Xiu Y; Wang S; Zhu J; Liu H; Ding X; Jin X; Zhao Z; Wang X
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):45-50. PubMed ID: 23619123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth.
    Coulter DW; Blatt J; D'Ercole AJ; Moats-Staats BM
    Anticancer Res; 2008; 28(3A):1509-16. PubMed ID: 18630505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting endocrine resistance: is there a role for mTOR inhibition?
    Sheri A; Martin LA; Johnston S
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment.
    LoRusso PM
    Oncology; 2013; 84(1):43-56. PubMed ID: 23128843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent patents and patent applications relating to mTOR pathway.
    Liu X; Yue Z
    Recent Pat DNA Gene Seq; 2009; 3(1):44-52. PubMed ID: 19149738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bidirectional regulation of nuclear factor-κB and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes.
    Dhingra R; Gang H; Wang Y; Biala AK; Aviv Y; Margulets V; Tee A; Kirshenbaum LA
    Circ Heart Fail; 2013 Mar; 6(2):335-43. PubMed ID: 23395931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroblastoma treatment in the post-genomic era.
    Esposito MR; Aveic S; Seydel A; Tonini GP
    J Biomed Sci; 2017 Feb; 24(1):14. PubMed ID: 28178969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zebrafish as a Neuroblastoma Model: Progress Made, Promise for the Future.
    Li S; Yeo KS; Levee TM; Howe CJ; Her ZP; Zhu S
    Cells; 2021 Mar; 10(3):. PubMed ID: 33800887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.
    Esposito MR; Binatti A; Pantile M; Coppe A; Mazzocco K; Longo L; Capasso M; Lasorsa VA; Luksch R; Bortoluzzi S; Tonini GP
    Int J Cancer; 2018 Nov; 143(10):2525-2536. PubMed ID: 29992558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell survival signaling in neuroblastoma.
    Megison ML; Gillory LA; Beierle EA
    Anticancer Agents Med Chem; 2013 May; 13(4):563-75. PubMed ID: 22934706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.